Silverfin false false 30/04/2024 01/05/2023 30/04/2024 Dr S K Bowler 20/08/2010 Dr M J Jordan 01/05/2023 Dr A E Stevens 01/02/2023 Dr R Veale 23/08/2013 Dr A S Vian 20/08/2010 Dr Richard Veale 03 October 2024 The principal activity of the company is that of the provision of medical services. 07351791 2024-04-30 07351791 bus:Director1 2024-04-30 07351791 bus:Director2 2024-04-30 07351791 bus:Director3 2024-04-30 07351791 bus:Director4 2024-04-30 07351791 bus:Director5 2024-04-30 07351791 2023-04-30 07351791 core:CurrentFinancialInstruments 2024-04-30 07351791 core:CurrentFinancialInstruments 2023-04-30 07351791 core:ShareCapital 2024-04-30 07351791 core:ShareCapital 2023-04-30 07351791 core:RevaluationReserve 2024-04-30 07351791 core:RevaluationReserve 2023-04-30 07351791 core:RetainedEarningsAccumulatedLosses 2024-04-30 07351791 core:RetainedEarningsAccumulatedLosses 2023-04-30 07351791 core:LandBuildings 2023-04-30 07351791 core:FurnitureFittings 2023-04-30 07351791 core:LandBuildings 2024-04-30 07351791 core:FurnitureFittings 2024-04-30 07351791 bus:OrdinaryShareClass1 2024-04-30 07351791 bus:OrdinaryShareClass2 2024-04-30 07351791 bus:OrdinaryShareClass3 2024-04-30 07351791 bus:OrdinaryShareClass4 2024-04-30 07351791 bus:OrdinaryShareClass5 2024-04-30 07351791 2023-05-01 2024-04-30 07351791 bus:FilletedAccounts 2023-05-01 2024-04-30 07351791 bus:SmallEntities 2023-05-01 2024-04-30 07351791 bus:AuditExemptWithAccountantsReport 2023-05-01 2024-04-30 07351791 bus:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 07351791 bus:Director1 2023-05-01 2024-04-30 07351791 bus:Director2 2023-05-01 2024-04-30 07351791 bus:Director3 2023-05-01 2024-04-30 07351791 bus:Director4 2023-05-01 2024-04-30 07351791 bus:Director5 2023-05-01 2024-04-30 07351791 bus:Director6 2023-05-01 2024-04-30 07351791 core:FurnitureFittings 2023-05-01 2024-04-30 07351791 2022-05-01 2023-04-30 07351791 core:LandBuildings 2023-05-01 2024-04-30 07351791 bus:OrdinaryShareClass1 2023-05-01 2024-04-30 07351791 bus:OrdinaryShareClass1 2022-05-01 2023-04-30 07351791 bus:OrdinaryShareClass2 2023-05-01 2024-04-30 07351791 bus:OrdinaryShareClass2 2022-05-01 2023-04-30 07351791 bus:OrdinaryShareClass3 2023-05-01 2024-04-30 07351791 bus:OrdinaryShareClass3 2022-05-01 2023-04-30 07351791 bus:OrdinaryShareClass4 2023-05-01 2024-04-30 07351791 bus:OrdinaryShareClass4 2022-05-01 2023-04-30 07351791 bus:OrdinaryShareClass5 2023-05-01 2024-04-30 07351791 bus:OrdinaryShareClass5 2022-05-01 2023-04-30 iso4217:GBP xbrli:pure xbrli:shares

Company No: 07351791 (England and Wales)

BRUNEL MEDICAL SERVICES LIMITED

Unaudited Financial Statements
For the financial year ended 30 April 2024
Pages for filing with the registrar

BRUNEL MEDICAL SERVICES LIMITED

Unaudited Financial Statements

For the financial year ended 30 April 2024

Contents

BRUNEL MEDICAL SERVICES LIMITED

BALANCE SHEET

As at 30 April 2024
BRUNEL MEDICAL SERVICES LIMITED

BALANCE SHEET (continued)

As at 30 April 2024
Note 2024 2023
£ £
Fixed assets
Tangible assets 3 794,496 789,848
794,496 789,848
Current assets
Debtors 4 44,495 89,179
Cash at bank and in hand 18,646 5,982
63,141 95,161
Creditors: amounts falling due within one year 5 ( 19,800) ( 28,500)
Net current assets 43,341 66,661
Total assets less current liabilities 837,837 856,509
Provision for liabilities ( 5,205) ( 3,845)
Net assets 832,632 852,664
Capital and reserves
Called-up share capital 6 9,999 9,999
Revaluation reserve 106,941 106,941
Profit and loss account 715,692 735,724
Total shareholders' funds 832,632 852,664

For the financial year ending 30 April 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Brunel Medical Services Limited (registered number: 07351791) were approved and authorised for issue by the Board of Directors on 03 October 2024. They were signed on its behalf by:

Dr Richard Veale
Director
BRUNEL MEDICAL SERVICES LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 April 2024
BRUNEL MEDICAL SERVICES LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 April 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Brunel Medical Services Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Centenary House Peninsula Park, Rydon Lane, Exeter, EX2 7XE, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Turnover

Turnover represents amounts receivable for all provision of medical and management services.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on tax rates and laws substantively enacted at the balance sheet date. Deferred tax assets and liabilities are not discounted.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a reducing balance basis over its expected useful life, as follows:

Land and buildings not depreciated
Fixtures and fittings 25 % reducing balance

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets receivable within one year, such as trade debtors and bank balances, are measured at transaction price less any impairment.

Basic financial assets receivable within more than one year are measured at amortised cost less any impairment.

Basic financial liabilities
Basic financial liabilities that have no stated interest rate and are payable within one year, such as trade creditors, are measured at transaction price.

Other basic financial liabilities are measured at amortised cost.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the year, including directors 0 0

3. Tangible assets

Land and buildings Fixtures and fittings Total
£ £ £
Cost
At 01 May 2023 770,000 83,325 853,325
Additions 0 10,109 10,109
At 30 April 2024 770,000 93,434 863,434
Accumulated depreciation
At 01 May 2023 0 63,477 63,477
Charge for the financial year 0 5,461 5,461
At 30 April 2024 0 68,938 68,938
Net book value
At 30 April 2024 770,000 24,496 794,496
At 30 April 2023 770,000 19,848 789,848

4. Debtors

2024 2023
£ £
Trade debtors 2,881 1,436
Accrued income 1,683 820
Other debtors 39,931 86,923
44,495 89,179

5. Creditors: amounts falling due within one year

2024 2023
£ £
Amounts owed to directors 0 6,000
Accruals 2,100 2,000
Taxation and social security 17,700 20,500
19,800 28,500

6. Called-up share capital

2024 2023
£ £
Allotted, called-up and fully-paid
1,765 Ordinary E shares of £ 1.00 each (2023: 3,000 shares of £ 1.00 each) 1,765 3,000
1,765 Ordinary F shares of £ 1.00 each (2023: 3,000 shares of £ 1.00 each) 1,765 3,000
2,352 Ordinary J shares of £ 1.00 each (2023: 3,999 shares of £ 1.00 each) 2,352 3,999
2,352 Ordinary H shares of £ 1.00 each (2023: nil shares) 2,352 0
1,765 Ordinary I shares of £ 1.00 each (2023: nil shares) 1,765 0
9,999 9,999

During the year 706 ordinary E shares, 706 ordinary F shares and 940 ordinary J shares, were reclassified as 2,352 ordinary H shares.

During the year 529 ordinary E shares, 529 ordinary F shares and 707 ordinary J shares, were reclassified as 1,765 ordinary I shares.

Rights, preferences and restrictions
The E, F, J, H and I ordinary shares have the following rights, preferences and restrictions:
The E, F, J, H and I ordinary shares all carry the same rights and privileges and rank pari passu in all respects, except that in respect of dividends. With regard to dividends, the directors shall not be bound to treat the E, F, J, H and I shares in the same manner.

7. Related party transactions

Other related party transactions

2024 2023
£ £
Amounts receivable from related party 95,580 86,923

Brunel Medical Practice
(The directors of the company are all partners within the Brunel Medical Practice partnership)

During the year a loan account existed between the company and the Brunel Medical Practice. The company charged the partnership £60,000 (2023: £60,000) for management services in the year. The company also made advances to the partnership in the year amounting to £67,491 (2023: £53,372). Repayments were received from the partnership during the year amounting to £118,834 (2023: £112,034). The loan between the company and the partnership is interest free and repayable on demand.